Burleson & Company, LLC Applied Molecular Transport Inc. Transaction History

Burleson & Company, LLC

  • $384 Million
  • Q4 2022

A detailed history of Burleson & Company, LLC transactions in Applied Molecular Transport Inc. stock. As of the latest transaction made, Burleson & Company, LLC holds 9,416 shares of AMTI stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,416
Previous 36,212 74.0%
Holding current value
$0
Previous $35,000 91.43%
% of portfolio
0.0%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 30, 2023
SELL
$0.35 - $1.26 $9,378 - $33,762
-26,796 Reduced 74.0%
9,416 $3,000
Q3 2022

Oct 17, 2022
SELL
$1.12 - $3.12 $42,101 - $117,283
-37,591 Reduced 50.93%
36,212 $35,000
Q1 2022

Apr 25, 2022
SELL
$5.63 - $13.88 $76,900 - $189,586
-13,659 Reduced 15.62%
73,803 $555,000
Q4 2021

Jan 25, 2022
SELL
$13.23 - $26.05 $354,762 - $698,530
-26,815 Reduced 23.46%
87,462 $1.22 Million
Q3 2021

Nov 02, 2021
BUY
$25.87 - $46.61 $206,960 - $372,880
8,000 Added 7.53%
114,277 $2.96 Million
Q2 2021

Jul 22, 2021
SELL
$39.76 - $64.31 $15,904 - $25,724
-400 Reduced 0.37%
106,277 $4.86 Million
Q1 2021

May 12, 2021
SELL
$30.5 - $74.14 $392,077 - $953,069
-12,855 Reduced 10.75%
106,677 $4.7 Million
Q4 2020

Feb 08, 2021
BUY
$29.39 - $35.0 $33,563 - $39,970
1,142 Added 0.96%
119,532 $3.68 Million
Q3 2020

Nov 10, 2020
BUY
$20.49 - $33.58 $143,430 - $235,060
7,000 Added 6.28%
118,390 $3.52 Million
Q2 2020

Aug 13, 2020
BUY
$17.98 - $28.0 $2 Million - $3.12 Million
111,390 New
111,390 $2.37 Million

Others Institutions Holding AMTI

# of Institutions
1
Shares Held
9.42K
Call Options Held
0
Put Options Held
0
View Full List

About Applied Molecular Transport Inc.

AMTI Quotes by TradingView
  • Ticker AMTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,900,600
  • Description
  • Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of r...
More about AMTI
Track This Portfolio

Track Burleson & Company, LLC Portfolio

Follow Burleson & Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Burleson & Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Burleson & Company, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email